Table 3. Vaccine class-based description of adverse reactions.

	Anthrax vaccines	Cholera vaccines	DTaP-IPV-Hib vaccines	Meningococcal vaccines	Pneumococcal vaccines	Tuberculosis vaccines	Typhoid vaccines	Encephalitis vaccines	Influenza vaccines	Hepatitis A vaccines	Hepatitis B vaccines	MMR vaccines	Rotavirus diarrhea vaccines	Zoster vaccines	Papillomavirus vaccines	COVID-19 mRNA vaccines	Ad5-vectored COVID-19 vaccines	Inactivated whole-virus COVID-19 vaccines	Other viral vaccines*	Others**
N observed	41	1	1,789	240	619	9	50	51	611	210	389	810	157	407	150	2,340	248	24	122	86
Age, years
0-11	1 (2.4)	0 (0.0)	1,520 (85.0)	149 (62.1)	441 (71.2)	0 (0.0)	9 (18.0)	30 (58.8)	191 (31.3)	123 (58.6)	203 (52.2)	712 (87.9)	143 (91.1)	292 (71.7)	15 (10.0)	51 (2.2)	0 (0.0)	4 (16.7)	5 (4.1)	8 (9.3)
12-17	0 (0.0)	0 (0.0)	46 (2.6)	38 (15.8)	0 (0.0)	4 (44.4)	1 (2.0)	3 (5.9)	21 (3.4)	15 (7.1)	26 (6.7)	27 (3.3)	0 (0.0)	9 (2.2)	79 (52.7)	71 (3.0)	0 (0.0)	0 (0.0)	0 (0.0)	4 (4.7)
18-44	37 (90.2)	0 (0.0)	73 (4.1)	20 (8.3)	14 (2.3)	2 (22.2)	32 (64.0)	10 (19.6)	94 (15.4)	40 (19.0)	98 (25.2)	27 (3.3)	0 (0.0)	9 (2.2)	28 (18.7)	706 (30.2)	70 (28.2)	13 (54.2)	111 (91.0)	42 (48.8)
45-64	1 (2.4)	0 (0.0)	43 (2.4)	1 (0.4)	36 (5.8)	0 (0.0)	2 (4.0)	5 (9.8)	106 (17.3)	17 (8.1)	28 (7.2)	6 (0.7)	0 (0.0)	28 (6.9)	0 (0.0)	592 (25.3)	96 (38.7)	2 (8.3)	4 (3.3)	20 (23.3)
≥65	0 (0.0)	0 (0.0)	18 (1.0)	2 (0.8)	95 (15.3)	0 (0.0)	3 (6.0)	2 (3.9)	160 (26.2)	2 (1.0)	6 (1.5)	1 (0.1)	0 (0.0)	50 (12.3)	0 (0.0)	380 (16.2)	62 (25.0)	5 (20.8)	2 (1.6)	2 (2.3)
Sex
Male	29 (70.7)	1 (100.0)	1,053 (58.9)	132 (55.0)	372 (60.1)	3 (33.3)	27 (54.0)	21 (41.2)	258 (42.2)	119 (56.7)	182 (46.8)	411 (50.7)	110 (70.1)	214 (52.6)	38 (25.3)	882 (37.7)	95 (38.3)	7 (29.2)	83 (68.0)	46 (53.5)
Female	12 (29.3)	0 (0.0)	687 (38.4)	103 (42.9)	232 (37.5)	5 (55.6)	21 (42.0)	30 (58.8)	340 (55.6)	88 (41.9)	196 (50.4)	371 (45.8)	46 (29.3)	190 (46.7)	111 (74.0)	1,406 (60.1)	141 (56.9)	17 (70.8)	37 (30.3)	37 (43.0)
Time to onset, days	1 (1-1)	730 (730-730)	1 (1-1)	1 (1-1)	1 (1-1)	1 (1-1)	1 (1-1)	1 (1-1)	1 (1-1)	1 (1-1)	1 (1-1)	1 (1-1)	1 (1-1)	1 (1-1)	1 (1-1)	1 (1-1)	1 (1-1)	1 (1-1)	1 (1-1)	1 (1-1)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4 (0.7)	0 (0.0)	1 (0.3)	2 (0.2)	0 (0.0)	1 (0.2)	1 (0.7)	14 (0.6)	4 (1.6)	0 (0.0)	0 (0.0)	0 (0.0)
Concomitant adverse events, %
Coronary	2.4	0.0	0.1	0.0	0.3	11.1	2.0	0.0	0.5	0.0	0.3	0.2	0.0	0.0	0.7	1.4	0.8	0.0	2.5	0.0
Arrhythmia	7.3	0.0	1.0	0.4	0.8	11.1	2.0	5.9	3.3	3.8	3.3	0.9	0.0	2.2	4.0	4.7	3.6	4.2	7.4	1.2
Heart failure	0.0	0.0	0.3	0.4	1.0	0.0	2.0	0.0	0.8	1.4	0.5	0.2	1.9	1.5	1.3	1.4	0.0	0.0	1.6	0.0
Other cardiac diseases	0.0	0.0	0.3	0.4	0.2	11.1	0.0	0.0	0.2	0.0	0.3	0.1	0.0	0.7	1.3	0.6	0.4	0.0	1.6	0.0
Hyperthermia	12.2	0.0	12.1	5.8	16.2	11.1	2.0	15.7	8.3	14.8	18.3	19.0	24.2	18.2	6.7	10.8	4.4	4.2	9.8	5.8
Eosinophilia	2.4	0.0	0.3	0.8	1.8	0.0	0.0	0.0	1.6	0.0	0.8	0.2	1.9	0.0	1.3	4.5	3.2	4.2	0.0	0.0
Thrombocytopenia and leucopenia	0.0	0.0	0.8	1.7	1.0	11.1	0.0	2.0	0.5	1.0	1.8	0.9	2.5	0.7	1.3	1.0	0.8	0.0	0.0	1.2
Pulmonary	2.4	0.0	1.4	2.9	2.1	11.1	4.0	0.0	1.8	2.4	1.5	1.5	3.2	2.9	4.7	1.8	1.6	0.0	0.8	1.2
Infections	7.3	0.0	3.1	4.2	4.2	22.2	4.0	0.0	3.9	6.7	10.3	7.0	7.0	11.8	5.3	5.5	1.2	0.0	4.9	5.8
Abdominal	0.0	0.0	1.4	2.9	2.4	11.1	0.0	2.0	2.5	4.3	2.8	2.2	7.0	1.5	4.7	3.1	1.2	0.0	0.0	1.2
Hepatobiliary	0.0	0.0	1.0	0.4	1.1	11.1	0.0	0.0	1.1	2.9	1.5	1.2	2.5	1.5	2.0	1.4	0.0	0.0	0.0	1.2
Renal	0.0	0.0	1.1	0.0	2.4	22.2	0.0	2.0	2.5	2.9	2.6	1.7	5.1	2.5	4.0	1.7	1.6	0.0	0.0	1.2
Endocrine	0.0	0.0	0.2	0.0	0.2	11.1	0.0	0.0	1.3	0.5	0.3	0.2	0.0	0.5	1.3	0.9	0.0	0.0	0.0	0.0
Muscular	9.8	0.0	0.6	1.3	2.1	11.1	0.0	3.9	2.9	2.4	1.8	1.1	0.0	1.7	2.0	5.5	5.6	0.0	3.3	3.5
Neurologic	17.1	0.0	2.6	2.5	4.2	11.1	8.0	0.0	4.9	5.7	6.4	4.0	3.8	6.4	10.7	14.6	11.7	8.3	7.4	3.5
Psychiatric	0.0	0.0	1.7	0.8	2.6	11.1	0.0	0.0	0.8	1.9	2.8	1.2	7.0	1.7	4.0	2.1	2.0	0.0	0.0	0.0
Osteoarticular and rheumatologic	2.4	0.0	2.1	3.8	2.3	11.1	4.0	3.9	4.1	5.7	6.7	3.1	1.9	3.9	7.3	5.7	3.6	0.0	2.5	7.0
Dermatologic	97.6	100.0	62.5	80.0	88.2	77.8	88.0	66.7	77.7	91.9	92.5	86.0	90.4	92.1	75.3	81.5	55.6	45.8	98.4	74.4
Anaphylaxis	0.0	0.0	1.8	3.8	2.4	11.1	2.0	0.0	2.0	2.4	3.3	2.0	3.2	2.5	0.0	2.6	1.6	0.0	1.6	1.2
Ophthalmology	2.4	0.0	0.8	3.3	1.1	11.1	0.0	0.0	0.8	1.9	1.5	2.2	1.3	1.5	2.7	1.2	1.6	0.0	0.0	1.2

The heatmap was expressed according to the percentage value.
Abbreviation: DTaP-IPV-Hib, diphtheria, tetanus toxoids, pertussis, polio, and Hemophilus influenza type b; IQR, interquartile range; MMR, measles, mumps, and rubella; TTO, time to onset; WHO, World Health Organization.
Other viral vaccines: Dengue virus, Ebola, enterovirus 71, monkeypox, respiratory syncytial virus, and smallpox vaccines.
Others: Brucellosis, leptospirosis, plague, and yellow fever vaccines.